Chester County News and Community Website
YARDLEY, PA — 314e Corporation’s flagship product, Jeeves, has received strong recognition in a new KLAS® Research Spotlight, highlighting its impact on electronic health record (EHR) adoption, training efficiency, and …
314e Corporation’s Jeeves Platform Earns Top Marks in KLAS® Research Spotlight Read More
YARDLEY, PA — Smart Sand, Inc. (NASDAQ: SND) reported a sharp increase in sales volumes and revenues for the second quarter of 2025, though higher logistics costs and negative cash …
Smart Sand Posts Strong Sales Growth Despite Cash Flow Pressures in Second Quarter Read More
NEW HOPE, PA — Cecilian Partners, a proptech firm specializing in community development technology, has secured the No. 547 spot on the 2025 Inc. 5000 list of the fastest-growing private …
Cecilian Partners Climbs to No. 547 on Inc. 5000 List, Marking Second Straight Year of Recognition Read More
LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) reported second-quarter 2025 financial results and outlined key regulatory and business milestones, including plans to resubmit its Biologics License Application (BLA) for MOLBREEVI, …
Savara to Resubmit BLA for Rare Lung Disease Treatment as Losses Widen in Q2 Read More
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has reported new clinical evidence suggesting its atrioventricular interval modulation (AVIM) therapy may significantly improve heart function in patients with …
Orchestra BioMed Study Shows AVIM Therapy Could Transform Care for Hypertensive Heart Disease Read More
NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) posted second-quarter 2025 results and outlined strategic progress on its antiviral drug pipeline, with a focus on COVID-19 and influenza treatments designed …
Traws Pharma Reports Q2 Results, Advances COVID-19 and Influenza Antiviral Programs Read More
LANGHORNE, PA — NEXGEL, Inc. (NASDAQ: NXGL) posted second-quarter 2025 revenue of $2.88 million, up 100.3% from the same period last year, as demand for its branded products and contract …
NEXGEL Doubles Q2 Revenue, Targets $13M in 2025 With Positive EBITDA Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) reported second-quarter 2025 results alongside a series of major financing and regulatory developments that position the company to advance its …
Orchestra BioMed Secures $111M to Advance Late-Stage Cardiac Therapies, Hits Multiple FDA Milestones Read More
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) reported encouraging early clinical results from its two lead oncology programs while narrowing its quarterly loss, according to second-quarter 2025 financial results …
Aprea Reports Positive Early Cancer Trial Results, Maintains Cash Runway Into 2026 Read More
WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced that interim Phase 2 trial data for its investigational therapy istaroxime will be presented at the Heart Failure Society of America’s …
Windtree Therapeutics Reports Promising Interim Results for Heart Failure Drug Candidate Read More